Perrigo Expects Retailers Will 'Push' OTC Private Label Market Share Growth
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Perrigo sees continued upside for digital sales of private label, given a “push marketing” approach that presents product ads to consumers shopping for branded products online, says CFO Ronald Winoweiecki. He also says the firm has not reached a decision on whether to divest its Rx generics business.
You may also be interested in...
Sensitivity To Flu Helped OTC Drug Firms End 2017 With Sales Boost
Cold and flu products performed “extraordinarily strong” wherever an influenza virus hit hardest, demonstrating “how understanding key incidents can really help tactical support and trade strategies at the local level,” market researcher says at CHPA exec conference.
Perrigo ANDA Approval Brings New Options To Generic Mucinex DM Maximum Strength Portfolio
Perrigo's first OTC drug approved in 2018 is extended-relief guaifenesin 1,200 mg and dextromethorphan 60 mg tablets, planned for launch under its own store brand, Goodsense, as well as distribution for retailer and private label brands. It already distributes the product for store and private label brands through an agreement with Teva.
Perrigo Finding Balance As Three-Legged Stool With Two Consumer Units, Rx Division
As new CEO Uwe Röhrhoff plans a "value creation" analysis, the improving Rx business growth could be essential for company because US competition from smaller, online brands is increasing in the OTC drug space and its sales of its consumer health products in Europe have yet to reach expectations.